The National Institute of Allergy and Infectious Diseases, the World Health Organization, and the Congolese government announced that 2 experimental antibody-based treatments for Ebola are working so well that they will now be offered to all patients in the Democratic Republic of Congo; enrollment in insurance exchanges under the Affordable Care Act remains stable for people with lower incomes who received subsidies, but premium increases caused a 24% decline for people who did not qualify for assistance; scientists are repurposing old drugs or combining them with traditional antibiotics in an effort to combat antibiotic-resistant bacteria.
The National Institute of Allergy and Infectious Diseases, the World Health Organization (WHO), and the Congolese government announced that 2 experimental antibody-based treatments for Ebola are working so well that they will now be offered to all patients in the Democratic Republic of Congo. The New York Times reported that officials hope the news will transform the course of the epidemic, which was declared a public health emergency last month and has killed more than 1800 people, according to the WHO.Enrollment in insurance exchanges under the Affordable Care Act remains stable for people with lower incomes who received subsidies, but premium increases caused a 24% decline for people who did not qualify for assistance, The Hill reported. CMS data shows that enrollment rose by 300,000 people among those with lower incomes who did qualify for financial help. Average ACA premiums fell by 1% between 2018 and 2019, reversing years of steep increases as many insurers stopped losing money in the market.Scientists are repurposing old drugs or combining them with traditional antibiotics in an effort to combat antibiotic-resistant bacteria, NPR reported. A recent study described the work of researchers at Brown, Emory, and Harvard universities who sought to find an existing drug that could target the bacteria's membrane, a part of the bacteria that most antibiotics don't attack. Bithionol, a drug formerly used to treat parasitic infections in horses, killed methicillin-resistant Staphylococcus aureus, a common hospital-acquired bug that causes pneumonia as well as infections.
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Complete Responses Seen With Emerging Therapies for Chronic Spontaneous Urticaria
April 16th 2025There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who are difficult to treat.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More